ChiCTR2600120171 版本V1.0 版本创建时间2026/03/10 14:57:13 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600120171 

最近更新日期:

Date of Last Refreshed on:

2026-03-10 14:57:05 

注册时间:

Date of Registration:

2026-03-10 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

0.01%阿托品滴眼液联合功能性离焦眼镜对儿童低度近视防控效果的临床研究

Public title:

Efficacy of 0.01% atropine eye drops combined with functional defocus spectacle lenses in controlling low myopia progression in children

注册题目简写:

English Acronym:

研究课题的正式科学名称:

0.01%阿托品滴眼液联合功能性离焦眼镜对儿童低度近视防控效果的临床研究

Scientific title:

Efficacy of 0.01% atropine eye drops combined with functional defocus spectacle lenses in controlling low myopia progression in children

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

侯艳华 

研究负责人:

赵琪 

Applicant:

Hou Yanhua 

Study leader:

Zhao Qi 

申请注册联系人电话:

Applicant telephone:

+86 187 5374 3959

研究负责人电话:

Study leader's
telephone:

+86 133 0411 2073

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

3036222130@qq.com

研究负责人电子邮件:

Study leader's E-mail:

zhaoqidmu@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国辽宁省大连市沙河口区中山路467号大连医科大学附属第二医院

研究负责人通讯地址:

中国辽宁省大连市沙河口区中山路467号大连医科大学附属第二医院

Applicant address:

The Second Affiliated Hospital of Dalian Medical University, 467 Shakou District, Dalian, Liaoning Province, China

Study leader's address:

The Second Affiliated Hospital of Dalian Medical University, 467 Shakou District, Dalian, Liaoning Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

大连医科大学附属第二医院

Applicant's institution:

The Second Affiliated Hospital of Dalian Medical University

研究负责人所在单位:

大连医科大学附属第二医院

Affiliation of the Leader:

The Second Affiliated Hospital of Dalian Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY2025-053-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

大连医科大学附属第二医院伦理委员会

Name of the ethic committee:

Ethics Committee of the Second Affiliated Hospital of Dalian Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-02-17 00:00:00

伦理委员会联系人:

任萍

Contact Name of the ethic committee:

Ren Ping

伦理委员会联系地址:

中国辽宁省大连市沙河口区大连医科大学附属第二医院行政中心6楼伦理办公室

Contact Address of the ethic committee:

Ethics Office, 6th Floor, Administrative Center, The Second Affiliated Hospital of Dalian Medical University, Shahekou District, Dalian, Liaoning Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 84671291

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

大连医科大学附属第二医院

Primary sponsor:

The Second Affiliated Hospital of Dalian Medical University

研究实施负责(组长)单位地址:

中国辽宁省大连市沙河口区中山路467号大连医科大学附属第二医院

Primary sponsor's address:

The Second Affiliated Hospital of Dalian Medical University, 467 Shakou District, Dalian, Liaoning Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

辽宁

市(区县):

大连

Country:

China

Province:

Liaoning

City:

Dalian

单位(医院):

大连医科大学附属第二医院

具体地址:

中国辽宁省大连市沙河口区中山路467号

Institution
hospital:

The Second Affiliated Hospital of Dalian Medical University

Address:

No. 467, Zhongshan Road, Shahekou District, Dalian City, Liaoning Province, China

经费或物资来源:

Source(s) of funding:

none

研究疾病:

近视  

Target disease:

myopia

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究通过研究0.01%阿托品滴眼液联合功能性离焦眼镜对于低度近视儿童防控效果,从而探讨该方法控制儿童近视的有效性和可行性。  

Objectives of Study:

In this study, the effect of 0.01% atropine eye drops combined with functional defocus glasses on the prevention and control of low myopia children was studied, so as to explore the effectiveness and feasibility of this method to control children's myopia.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄7-12岁 2.睫状肌麻痹验光后等效球镜度数 -0.50D—-3.00D 散光≤-1.50D 3.BCVA ≥1.0 4.眼压10-21mmHg

Inclusion criteria

1.Age 7-12 years old 2.Equivalent spherical power after cycloplegia optometry-0.50 D--3.00 D Astigmatism ≤-1.50 D 3.BCVA ≥ 1.0 4.Intraocular pressure 10-21mmHg

排除标准:

1.近视力不佳或调节能力差 2.既往使用过角膜塑形镜、隐形眼镜等防控方法 3.斜视、弱视及其他眼部疾病或眼部手术史者 4.对本研究药物过敏

Exclusion criteria:

1.Poor near vision or poor adjustment ability 2.Previous use of orthokeratology lenses, contact lenses and other prevention and control methods 3.Strabismus, amblyopia and other eye diseases or history of eye surgery 4.Allergy to the drugs in this study

研究实施时间:

Study execute time:

From 2025-02-18 00:00:00 To 2026-05-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-02-18 00:00:00 To 2026-05-31 00:00:00

干预措施:

Interventions:

组别:

0.01%阿托品滴眼液联合离焦眼镜组

样本量:

30

Group:

0.01% atropine eye drops combined with functional defocus glasses

Sample size:

干预措施:

同时使用0.01%阿托品滴眼液和离焦眼镜两种防控措施

干预措施代码:

Intervention:

Use 0.01% atropine eye drops and defocus glasses at the same time as two prevention and control measures

Intervention code:

组别:

单用0.01%阿托品组

样本量:

30

Group:

0.01% atropine eye drops alone

Sample size:

干预措施:

0.01%阿托品滴眼液,每晚睡前1次

干预措施代码:

Intervention:

0.01% atropine eye drops, once a night before bed

Intervention code:

组别:

单用离焦眼镜组

样本量:

30

Group:

functional defocus glasses alone

Sample size:

干预措施:

每天戴眼镜大于12小时

干预措施代码:

Intervention:

Wear glasses for more than 12 hours a day

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

辽宁 

市(区县):

大连 

Country:

China

Province:

Liaoning

City:

Dalian

单位(医院):

大连医科大学附属第二医院 

单位级别:

三甲 

Institution
hospital:

The Second Affiliated Hospital of Dalian Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

眼轴

指标类型:

主要指标

Outcome:

Axial length

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

等效球镜度

指标类型:

次要指标

Outcome:

spherical equivalent refraction

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

黄斑中央凹下脉络膜厚度

指标类型:

次要指标

Outcome:

Subfoveal Choroidal Thickness

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 7 years
最大 Max age 12 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

使用excel表生成随机数

Randomization Procedure (please state who generates the random number sequence and by what method):

Generate random numbers using an Excel spreadsheet

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

none

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

论文发表后半年内,国家人口健康科学数据中心,https://www.ncmi.cn/index.html

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Within six months after the paper is published,National Population Health Science Data Center, https://www.ncmi.cn/index.html

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case record sheet

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-03-10 14:57:05